Utrogestan Mechanism of Action

Progesterone (Utrogestan), which contains progesterone in micronised form, significantly increases plasma progesterone levels following oral and vaginal administration, thus making it possible to correct any deficits in progesterone.
Elevation of blood progesterone levels starts from the first hour onwards, with peak plasma levels reached within 1-3 hours following administration.
Metabolisation: plasma and urinary metabolites are identical to those found during physiological corpus luteum secretion. Its main plasma metabolites include 20-alpha-hydroxy-delta-4-pregnenolone and 5-alpha-dihydroprogesterone. Urinary elimination occurs at a rate of 95% in the form of glucuronide-conjugated metabolites. Its main urinary metabolite is 3-alpha-5-beta pregnanediol (pregnandiol).
Oral: Owing to the tissue retention time of the hormone, it might be prudent to divide the dosage into two doses, to be taken at 12-hourly intervals approx., in order to ensure that impregnation is obtained throughout the entire 24-hour period.
Vaginal: At the standard recommended dose, stable physiological levels of plasma progesterone, similar to those obtained during the luteal phase of a normal, ovulatory menstrual cycle, can be reached and maintained.
Progesterone (Utrogestan) Vaginal soft capsules, induce adequate endometrial maturity, thus promoting embryo implantation.
At higher doses, reached via gradual upward titration, this route of administration makes it possible to achieve blood progesterone levels similar to those observed during the first trimester of pregnancy.